ArticleFrontiers in oncology2022

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.

Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.